The problem we see with this option is that conventional BGM cannot be saved and Animas needs some serious money to become competitive. We suppose it's possible that JNJ could approach Dexcom (NASDAQ: DXCM), yes Dexcom and offer to finance a deal which would prevent Dexcom from using their own money. Dexcom then in turn could use the LifeScan installed user base as the launching pad for their Band-Aid sensor they are working on with Google. Having Animas Dexcom could also at least partially blunt Medtronic (NYSE: MDT) who not only has the 670G but is moving aggressively into the stand-alone CGM market.